Therefore, the study hypothesis of the second Czech nationwide screening of FD in ESKD patients on MDT was not only to (i) assess the efficacy of applied FD screening recommendations, but also to analyze (ii) whether the combination of two FD-associated biomarkers (i.e. GALA and lyso-Gb3 level examination) together with GLA sequencing/advanced bioinformatic analyses could identify additional/atypical cases of FD that could have been missed by the previous FD screening methodology and assure an equitable screening approach in male and female subjects with ESKD. The gene discussed is GLA; the disease is Fabry disease.